National Institute for Clinical Excellence

Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma

1. Guidance

1.1 For children under the age of 5 years with chronic stable asthma both corticosteroids and bronchodilator therapy should be routinely delivered by pressurised metered dose inhaler (pMDI) and spacer system, with a facemask where necessary.

1.2 Where this combination is not clinically effective for the child and depending on the child's condition, nebulised therapy may be considered and in the case of children aged 3 to 5 years, a dry powder inhaler (DPI) may also be considered.

1.3 Choice of device to be made within the pMDI and spacer range should be primarily governed by specific individual need and the likelihood of good compliance. Once these factors have been taken into account, choice should be made on the basis of cost minimisation.

This section, Section 1, constitutes the Institute's Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma. The remainder of the document is structured in the following way:

2 Clinical Need and Practice
3 The Technology
4 Evidence
5 Implications for the NHS
6 Related Guidance
7 Further Research
8 Implementation
9 Clinical Audit Advice
10 Review of Guidance
Appendix A: Appraisal Committee
Appendix B: Sources of Evidence
Appendix C: Information for Patients.

The full document and a Summary of Evidence are available from our website at www.nice.org.uk or by telephoning 0541 555 455 and quoting the reference number 22197.

Issue Date August 2000
Review Date August 2003

Technology Appraisal Guidance No. 10

ISBN: 1-84257-034-X

00001P 1k Aug 00 (ABA)

Sefydliad Cenedlaethol ar gyfer Rhagoriaeth Glinigol

Arweiniad ar ddefnyddio systemau (dyfeisiau) anadlu mewn plant o dan 5 oed sydd ag asthma cronig

Dyddiad Cyhoeddi: Awst 2000

Dyddiad Arolygu: Awst 2003

Arweiniad ar Arfarnu Technoleg Rhif 10

1 Arweiniad

1.1 I blant o dan 5 oed ag asthma sefydlog cronig, dylid rhoi corticosteroidau a therapi broncoledydd fel mater o drefn, drwy anadlydd gwasgeddedig dogn mesuredig (pMDI) a system bylchau, gyda masg wyneb lle bo angen.

1.2 Lle nad yw'r cyfuniad hwn yn effeithiol yn glinigol ar gyfer y plentyn ac yn dibynnu ar gyflwr y plentyn, hwyrach yr ystyrir therapi nebwleiddio, ac yn achos plant rhwng 3 a 5 oed, hwyrach yr ystyrir anadlydd powdr sych (DPI) hefyd.

1.3 Angen penodol yr unigolyn a thebygolrwydd cydymffurfiaeth dda ddylai reoli'r dewis o ddyfais o fewn yr ystod pMDI a bylchau. Unwaith y mae'r ffactorau hyn wedi eu hystyried, dylid dewis ar sail lleihau costau.

Mae'r adran hon, sef Adran 1, yn ffurfio Arweiniad y Sefydliad ar ddefnyddio systemau (dyfeisiau) anadlu mewn plant o dan 5 oed sydd ag asthma cronig. Mae gweddill y ddogfen wedi ei strwythuro fel a ganlyn:

2 2. Angen ac Arfer Clinigol
3 Y Dechnoleg
4 Tystiolaeth
5 Goblygiadau i'r NHS
6 Arweiniad Perthnasol
7 Rhagor o Ymchwil
8 Gweithredu
9 Cyngor Archwilio Clinigol
10 Arolygu'r Arweiniad
- Atodiad A: Pwyllgor Arfarnu
- Atodiad B: Ffynonellau Tystiolaeth
- Atodiad C: Gwybodaeth i Gleifion

Gallwch gael y ddogfen lawn a Chrynodeb o'r Dystiolaeth o'n gwefan yn www.nice.org.uk neu drwy ffonio 0541 555 455 a dyfynnu'r rhif cyfeirnod 22197.